SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

BMN 333

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2/3
Time to market
If successful through Phase 2/3, potential launch is estimated around 2030 per earlier BioMarin guidance, though the timeline depends on Phase 2/3 results and regulatory interactions.
Why 4/10
The next hard, dated catalyst is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given, more than 12 months from today). With no near-term binary catalyst and BMN 333 being one of several pipeline assets at a diversified rare-disease company with nine marketed products, the impact score is a default 4.
Actionable Insight NEUTRAL

The next catalyst for BMN 333 is dose-response data from the Phase 2/3 dose-finding segment, expected in 2027 (no specific date given). Positive data would validate a weekly, potentially superior alternative to Voxzogo and strengthen BioMarin's achondroplasia franchise against Ascendis' newly approved Yuviwel. Negative or underwhelming data would raise doubts about the drug's best-in-class potential and could pressure BMRN shares given the competitive threat.

Price Chart

Loading chart...

Executive Summary

BMN 333 is BioMarin's investigational long-acting C-type natriuretic peptide (CNP) for achondroplasia, designed as a once-weekly subcutaneous injection versus the daily injections required by its predecessor Voxzogo (vosoritide). Phase 1 data presented at ENDO 2026 showed favorable safety and supported weekly dosing. A registration-enabling Phase 2/3 study (NCT07441876) began enrolling in April 2026 and continues on track, with dose-response data from the dose-finding segment expected in 2027. The competitive landscape shifted significantly in February 2026 when Ascendis Pharma received FDA approval for Yuviwel (navepegritide), the first once-weekly CNP for achondroplasia. BMN 333 is a mid-to-late-stage pipeline asset at a diversified rare-disease company with nine marketed products and over $1 billion in quarterly revenue, meaning its impact on BMRN's share price is moderated by the broader portfolio and the distant timeline to commercialization.

How It Works

BMN 333 is a long-acting version of BioMarin's existing drug Voxzogo (vosoritide). Achondroplasia, the most common form of dwarfism, is caused by a genetic mutation that over-suppresses bone growth. BMN 333 is a C-type natriuretic peptide (CNP) that counteracts this suppression and stimulates bone growth. It is designed as a prodrug that slowly releases the active medication over a week, so patients would need only one injection per week instead of a daily shot. The drug uses a biodegradable hydrogel technology to achieve this extended release.

Trial Status

Phase 1 single ascending dose study in healthy adults completed with favorable safety and PK supporting weekly dosing. Phase 2/3 registration-enabling study (NCT07441876) began enrolling in April 2026, is a randomized, active-controlled, operationally seamless trial comparing BMN 333 against vosoritide in treatment-naive children with achondroplasia. The Phase 2 dose-finding segment is ongoing; dose-response data expected in 2027. Primary completion of the full study is estimated around June 2029.

The Two-Sided Case

▲ Bull Case5
Phase 1 data showed BMN 333 achieved >13x higher free CNP exposure versus another long-acting CNP agent, with favorable safety and no dose-limiting toxicities, supporting once-weekly dosing.
BioMarin management describes BMN 333 as a 'potential best-in-class molecule' with opportunity to drive greater improvements in growth parameters versus available therapies.
BMN 333 is designed as a weekly subcutaneous injection versus Voxzogo's daily injection, a significant convenience advantage that could drive patient and physician adoption.
The drug leverages BioMarin's deep expertise in the achondroplasia space, with an established commercial infrastructure and KOL relationships from Voxzogo.
BioMarin reported Q3 2026 revenue above $1 billion for the first time (up 32% YoY), demonstrating financial strength to fund the BMN 333 program through completion.
▼ Bear Case5
Ascendis Pharma's Yuviwel (navepegritide) was FDA-approved on February 27, 2026 as the first once-weekly CNP for achondroplasia, establishing a direct competitive head start while BMN 333 is still in Phase 2/3 trials.
BMN 333 is years from potential approval (estimated launch around 2030 per earlier BioMarin guidance), giving competitors time to capture market share.
The Phase 2/3 trial is active-controlled against BioMarin's own Voxzogo, creating a high bar: the drug must demonstrate superiority or at least non-inferiority with less frequent dosing to justify switching.
BioMarin carries significant debt from the Amicus acquisition, and pipeline failures could strain resources.
Dose-response data is not expected until 2027, meaning no near-term catalyst to derisk the program for more than a year.

Upcoming Catalysts

  • Dose-response data from the Phase 2/3 dose-finding segment expected in 2027 (no specific date given)
  • PDUFA action date of May 30, 2027 for VOXZOGO in hypochondroplasia (a separate BioMarin catalyst)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 17

Hover a chip for the title
1 biomarin.com2 biomarin.com3 prnewswire.com4 prnewswire.com5 finance.biggo.com6 investors.ascendispharma.com7 drugs.com8 adisinsight.springer.com9 clinicaltrials.gov10 medical.biomarin.com11 fiercepharma.com12 medical.biomarin.com13 medical.biomarin.com14 medical.biomarin.com15 pnas.org16 biomarin.com17 marketbeat.com